Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO

被引：0

作者：

Thorsten O. Götze

Pompiliu Piso

Sylvie Lorenzen

Ulli S. Bankstahl

Claudia Pauligk

Moustafa Elshafei

Giuseppe Amato

Daniel Reim

Wolf O. Bechstein

Alfred Königsrainer

Stefan P. Mönig

Beate Rau

Matthias Schwarzbach

Salah-Eddin Al-Batran

机构：

[1] Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest,Department for General and Visceral Surgery

[2] UCT-University Cancer Center,Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum Rechts der Isar

[3] Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,Department of General Surgery and Emergency

[4] Hospital Barmherzige Brueder,Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar

[5] University of Regensburg,Department of General and Visceral Surgery

[6] Technische Universitat Munchen,Department of General

[7] Bariatrische und Metabolische Chirurgie,, Visceral Surgery and Transplantation

[8] Krankenhaus Nordwest,Service de Chirurgie viscérale

[9] University of Palermo,Department of Surgery

[10] Technische Universität München,undefined

[11] University Hospital Frankfurt,undefined

[12] University Hospital Tübingen,undefined

[13] Hôpitaux Universitaires de Genève,undefined

[14] Campus Charité Mitte,undefined

[15] Campus Virchow-Klinikum CCM/CVK,undefined

[16] Clinic for General,undefined

[17] Visceral,undefined

[18] Vascular and Thoracic Surgery,undefined

[19] Klinikum Frankfurt Höchst,undefined

来源：

BMC Cancer | / 21卷

关键词：

Gastric cancer; Gastroesophageal junction cancer; Lauren- classification; Signet ring cells; HIPEC; Hyperthermic intraperitoneal chemotherapy; FLOT- regimen; Gastrectomy; Quality of life; Cisplatin; Peritoneal carcinomatosis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 40 条

[31] Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
Pauligk, Claudia
Tannapfel, Andrea
Meiler, Johannes
Luley, Kim Barbara
Kopp, Hans-Georg
Homann, Nils
Hofheinz, Ralf Dieter
Schmalenberg, Harald
Probst, Stephan
Haag, Georg Martin
Egger, Matthias
Behringer, Dirk M.
Stoehlmacher, Jan
Prasnikar, Nicole
Block, Andreas
Trojan, Jorg
Koenigsmann, Michael
Schmiegel, Wolff
Jaeger, Elke
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[32] The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI
Al-Batran, Salah-Eddin
Goetze, Thorsten O.
Mueller, Daniel W.
Vogel, Arndt
Winkler, Michael
Lorenzen, Sylvie
Novotny, Alexander
Pauligk, Claudia
Homann, Nils
Jungbluth, Thomas
Reissfelder, Christoph
Caca, Karel
Retter, Steffen
Horndasch, Eva
Gumpp, Julia
Bolling, Claus
Fuchs, Karl-Hermann
Blau, Wolfgang
Padberg, Winfried
Pohl, Michael
Wunsch, Andreas
Michl, Patrick
Mannes, Frank
Schwarzbach, Matthias
Schmalenberg, Harald
Hohaus, Michael
Scholz, Christian
Benckert, Christoph
Knorrenschild, Jorge Riera
Kanngiesser, Veit
Zander, Thomas
Alakus, Hakan
Hofheinz, Ralf-Dieter
Roedel, Claus
Shah, Manish A.
Sasako, Mitsuru
Lorenz, Dietmar
Izbicki, Jakob
Bechstein, Wolf O.
Lang, Hauke
Moenig, Stefan P.
BMC CANCER, 2017, 17
[33] The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
Salah-Eddin Al-Batran
Thorsten O. Goetze
Daniel W. Mueller
Arndt Vogel
Michael Winkler
Sylvie Lorenzen
Alexander Novotny
Claudia Pauligk
Nils Homann
Thomas Jungbluth
Christoph Reissfelder
Karel Caca
Steffen Retter
Eva Horndasch
Julia Gumpp
Claus Bolling
Karl-Hermann Fuchs
Wolfgang Blau
Winfried Padberg
Michael Pohl
Andreas Wunsch
Patrick Michl
Frank Mannes
Matthias Schwarzbach
Harald Schmalenberg
Michael Hohaus
Christian Scholz
Christoph Benckert
Jorge Riera Knorrenschild
Veit Kanngießer
Thomas Zander
Hakan Alakus
Ralf-Dieter Hofheinz
Claus Roedel
Manish A. Shah
Mitsuru Sasako
Dietmar Lorenz
Jakob Izbicki
Wolf O. Bechstein
Hauke Lang
Stefan P. Moenig
BMC Cancer, 17
[34] Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO.
Koock, Ulrike
Pauligk, Claudia
Luley, Kim Barbara
Mayer, Frank
Schulmann, Karsten
Homann, Nils
Schmalenberg, Harald
Hozaeel, Wael
Hofheinz, Ralf
Probst, Stephan
Mahlberg, Rolf
Koenigsmann, Michael
Haag, Georg Martin
Meiler, Johannes
Prasnikar, Nicole
Behringer, Dirk M.
Trojan, Jorg
Egger, Matthias
Jaeger, Elke
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[35] Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
Reynolds, John V.
Preston, Shaun R.
O'Neill, Brian
Lowery, Maeve Aine
Baeksgaard, Lene
Crosby, Thomas
Cunningham, Moya
Cuffe, Sinead
Griffiths, Gareth Owen
Roy, Rajarshi
Falk, Stephen
Hanna, George
Bartlett, Frederick R.
Parker, Imelda
Alvarez-Iglesias, Alberto
Nilsson, Magnus
Piessen, Guillaume
Risum, Signe
Ravi, Narayanasamy
McDermott, Raymond S.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: A one-arm open-table phase II trial
Li, Hongli
Ge, Shaohua
Zang, Fenglin
Ren, Peng
Cao, Fuliang
Liu, Rui
Yang, Yuchong
Ning, Tao
Bai, Ming
Wang, Xia
Ji, Zhi
Duan, Jingjing
Liang, Han
Ba, Yi
Deng, Ting
Deng, Jingyu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Al-Batran, Salah-Eddin
Homann, Nils
Pauligk, Claudia
Goetze, Thorsten O.
Meiler, Johannes
Kasper, Stefan
Kopp, Hans-Georg
Mayer, Frank
Haag, Georg Martin
Luley, Kim
Lindig, Udo
Schmiegel, Wolff
Pohl, Michael
Stoehlmacher, Jan
Folprecht, Gunnar
Probst, Stephan
Prasnikar, Nicole
Fischbach, Wolfgang
Mahlberg, Rolf
Trojan, Joerg
Koenigsmann, Michael
Martens, Uwe M.
Thuss-Patience, Peter
Egger, Matthias
Block, Andreas
Heinemann, Volker
Illerhaus, Gerald
Moehler, Markus
Schenk, Michael
Kullmann, Frank
Behringer, Dirk M.
Heike, Michael
Pink, Daniel
Teschendorf, Christian
Loehr, Carmen
Bernhard, Helga
Schuch, Gunter
Rethwisch, Volker
von Weikersthal, Ludwig Fischer
Hartmann, Joerg T.
Kneba, Michael
Daum, Severin
Schulmann, Karsten
Weniger, Joerg
Belle, Sebastian
Gaiser, Timo
Oduncu, Fuat S.
Guentner, Martina
Hozaeel, Wael
Reichart, Alexander
LANCET, 2019, 393 (10184): : 1948 - 1957
[38] Phase I/II study of nab-paclitaxel combined with S-1 as adjuvant chemotherapy in diffuse type of stage III gastric or gastroesophageal junction adenocarcinoma
Cui, Yuehong
Wei, Jia
Yu, Yiyi
Xu, Bei
Wu, Jing
Xu, Xiaojing
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Al-Batran, Salah-Eddin
Hofheinz, Ralf D.
Pauligk, Claudia
Kopp, Hans-Georg
Haag, Georg Martin
Luley, Kim Barbara
Meiler, Johannes
Homann, Nils
Lorenzen, Sylvie
Schmalenberg, Harald
Probst, Stephan
Koenigsmann, Michael
Egger, Matthias
Prasnikar, Nicole
Caca, Karel
Trojan, Joerg
Martens, Uwe M.
Block, Andreas
Fischbach, Wolfgang
Mahlberg, Rolf
Clemens, Michael
Illerhaus, Gerald
Zirlik, Katja
Behringer, Dirk M.
Schmiegel, Wolff
Pohl, Michael
Heike, Michael
Ronellenfitsch, Ulrich
Schuler, Martin
Bechstein, Wolf O.
Koenigsrainer, Alfred
Gaiser, Timo
Schirmacher, Peter
Hozaeel, Wael
Reichart, Alexander
Goetze, Thorsten O.
Sievert, Mark
Jaeger, Elke
Moenig, Stefan
Tannapfel, Andrea
LANCET ONCOLOGY, 2016, 17 (12): : 1697 - 1708
[40] Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)
Li, C.
Zheng, Y.
Shi, Z.
Yang, L.
Zhang, B.
Wang, Z.
Chen, H.
Wang, X.
Zhao, P.
Dong, J.
Lian, C.
Zhao, Q.
Zheng, Z.
Zhang, A.
Xu, S.
Wang, K.
Yuan, F.
Tian, Y.
Yin, K.
Zhu, Z.
ANNALS OF ONCOLOGY, 2023, 34 : S852 - S852

← 1 2 3 4 →